Skip to main content
Clinical Trials/EUCTR2020-001435-27-FR
EUCTR2020-001435-27-FR
Active, not recruiting
Phase 1

Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safetyof several experimental treatments to reduce the risk of hospitalization or death(COVERAGE trial) - COVERAGE

CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC0 sites845 target enrollmentApril 1, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
severe acute respiratory syndrome coronavirus 2(SARS-CoV 2)
Sponsor
CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC
Enrollment
845
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 1, 2020
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC

Eligibility Criteria

Inclusion Criteria

  • ? Positive SARS\-CoV\-2 test on nasopharyngeal swab
  • ? Onset of symptoms \< 5 days prior to nasopharyngeal swabbing
  • ? Age \= 60 years old
  • ? Valid, ambulatory person, fully capable of understanding the challenges of the trial
  • ? No hospitalization criteria according to current recommendations
  • ? Signed informed consent
  • ? Covered by Health Insurance
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) no

Exclusion Criteria

  • ?Inability to make a decision to participate (dementia, guardianship)
  • ?Long QT syndrome, or QTc space \> 500 ms
  • ?Heart rate \<50 / min
  • ?Hyperkalemia \> 5\.5 mmol/L or hypokalemia \< 3\.5 mmol/L
  • ?Treatment with dasatinib, nilotinib, ibrutinib, , potent inhibitors of cytochrome P450 CYP3A4 isoenzyme, potent inducers of cytochrome P450 CYP3A4 isoenzyme, repaglinide, azathioprine, 6\-mercaptopurine, theophylline, pyrazinamide, warfarin.
  • ?Hypersensitivity to any of the trial drugs, , ARA2 or sartan.
  • ?Liver failure (stage \= Child\-Pugh B), stage 4 or 5 chronic kidney disease (DFG \<30 mL/min/1\.73 m²), person on dialysis, malabsorption syndrome, symptomatic gout/hyperuricemia, ileus, colitis or enterocolitis, chronic infection with the hepatitis B virus.

Outcomes

Primary Outcomes

Not specified

Similar Trials